Skip to main content Skip to navigation
Purified Mouse anti-PLK1 (pT210)
Purified Mouse anti-PLK1 (pT210)
Western blot analysis of PLK1 (pT210) in transformed human epithelioid carcinoma.  Lysates from HeLa S3 cell line were probed with purified mouse anti-PLK1 (pT210) monoclonal antibody at concentrations of 0.063, 0.032, and 0.016 µg/ml (Lanes 1, 2, and 3, respectively) with (left panel) or without (right panel) lambda protein phosphatase treatment.  PLK1 (pT210) is identified as a band of 68 kDa in the untreated cells.
Western blot analysis of PLK1 (pT210) in transformed human epithelioid carcinoma.  Lysates from HeLa S3 cell line were probed with purified mouse anti-PLK1 (pT210) monoclonal antibody at concentrations of 0.063, 0.032, and 0.016 µg/ml (Lanes 1, 2, and 3, respectively) with (left panel) or without (right panel) lambda protein phosphatase treatment.  PLK1 (pT210) is identified as a band of 68 kDa in the untreated cells.
Product Details
Down Arrow Up Arrow


BD Pharmingen™
Human (QC Testing), Mouse (Predicted)
Mouse IgG1, κ
Phosphorylated Human PLK1 Peptide
Western blot (Routinely Tested)
68 kDa
0.5 mg/ml
AB_647292
Aqueous buffered solution containing ≤0.09% sodium azide.
RUO


Preparation And Storage

Store undiluted at 4°C. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Product Notices

  1. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  2. Sodium azide is a reversible inhibitor of oxidative metabolism; therefore, antibody preparations containing this preservative agent must not be used in cell cultures nor injected into animals. Sodium azide may be removed by washing stained cells or plate-bound antibody or dialyzing soluble antibody in sodium azide-free buffer. Since endotoxin may also affect the results of functional studies, we recommend the NA/LE (No Azide/Low Endotoxin) antibody format, if available, for in vitro and in vivo use.
  3. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
558400 Rev. 3
Antibody Details
Down Arrow Up Arrow
K50-483

Polo-like kinase (PLK1) is a serine/threonine kinase with structural similarities to Drosophila's Polo kinase and the Cdc5p of Saccharomyces cerevisiae.  Like its invertebrate counterparts, PLK1 activity is required for DNA synthesis and is regulated throughout the cell cycle.  Furthermore, PLK1 is highly expressed in primary tumors.  It associates with the mitotic spindle during mitosis suggesting that, in addition to its role during S phase, PLK1 may play a role during chromosome segregation.  This is consistent with its potential role in cancer development.  Threonine 210 (T210) is one of the major phoshorylation sites in activated PLK1 obtained from human mitotic cells.

The K50-483 monoclonal antibody recognizes the phosphorylated T210 of human PLK1.

558400 Rev. 3
Format Details
Down Arrow Up Arrow
Purified
Tissue culture supernatant is purified by either protein A/G or affinity purification methods. Both methods yield antibody in solution that is free of most other soluble proteins, lipids, etc. This format provides pure antibody that is suitable for a number of downstream applications including: secondary labeling for flow cytometry or microscopy, ELISA, Western blot, etc.
Purified
558400 Rev.3
Citations & References
Down Arrow Up Arrow

Development References (4)

  1. Ando K, Ozaki T, Yamamoto H, et al. Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem. 2004; 279(24):25549-25561. (Biology).
  2. Jang Y-J, Ma S, Terada Y, Erikson RL. Phosphorylation of threonine 210 and the role of serine 137 in the regulation of mammalian Polo-like kinase. J Biol Chem. 2002; 277(46):44115-44120. (Biology).
  3. Peter B, Gleixner K, Cerny-Reiterer S, et al. Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the polo-like kinase-1 targeting drug BI 2536. Haematologica. 2011; 96(5):672-680. (Clone-specific: Immunocytochemistry (cytospins)). View Reference
  4. Yamashiro S, Yamakita Y, Totsukawa G, et al. Myosin phosphatase targeting subunit1 regulates mitosis by antagonizing polo-like kinase1. Dev Cell. 2008; 14(5):787-797. (Clone-specific: Immunofluorescence, Western blot). View Reference
View All (4) View Less
558400 Rev. 3

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.